<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39257909</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by <i>acinetobacter baumannii-calcoaceticus</i> complex: A narrative review.</ArticleTitle><Pagination><StartPage>e70066</StartPage><MedlinePgn>e70066</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70066</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.70066</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Infections caused by <i>Acinetobacter baumannii</i>, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) resulting from the <i>A. baumannii-calcoaceticus</i> (ABC) complex represent a major clinical challenge. This review aimed to understand the approval process, mechanism of action, therapeutic potential, and future implications of sulbactam-durlobactam therapy (SUL-DUR).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">PubMed, Web of Science, EMBASE, Clinical trials. gov, ICTRP, and CENTRAL were searched for studies on SUL-DUR for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Also, World Health Organization, U.S. Food and Drug Administration, and Centers for Disease Control and Prevention websites were searched for relevant information.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">SUL-DUR, marketed as Xacduro, is a novel pharmaceutical combination that functions as a narrow-spectrum parenterally administered antibiotic. Sulbactam acts as a β-lactamase inhibitor, whereas durlobactam protects against degradation by <i>A. baumannii</i> enzymes. A phase 1 trial successfully established the safety and tolerability of SUL-DUR in patients with normal and mild renal impairment. A phase 2 trial demonstrated the safety and tolerability of SUL-DUR in a larger population with urinary tract infections. A phase 3 trial showed that SUL-DUR was non-inferior to colistin in terms of mortality in <i>A. baumannii-related</i> VAP, HAP, and bacteremia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The combination of sulbactam and durlobactam is a promising treatment option for HAP and VAP caused by ABC complex.</AbstractText><CopyrightInformation>© 2024 The Author(s). Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Ayush</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0279-4636</Identifier><AffiliationInfo><Affiliation>B. P. Koirala Institute of Health Sciences Dharan Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MediSurg Research Darbhanga India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Amogh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rama Medical College Hospital and Research Centre Hapur India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaur</LastName><ForeName>Sarabjeet</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Government Medical College Patiala India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kathayat</LastName><ForeName>Priyangi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Smt. NHL Municipal Medical College Ahmedabad India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manoj</LastName><ForeName>Rachel M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nicolae Testemițanu State University of Medicine and Pharmacy Chisinau Moldova.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aakanksha</LastName><ForeName>Aakanksha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tbilisi State Medical University Tbilisi Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turzin</LastName><ForeName>Justice K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Global Consortium of Medical Education and Research Pune India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Health and Allied Sciences University of Cape Coast Cape Coast Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satapathy</LastName><ForeName>Prakasini</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospital Saveetha University Chennai India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Laboratories Techniques Department AL-Mustaqbal University Hillah Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khatib</LastName><ForeName>Mahalaqua N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Division of Evidence Synthesis, Datta Meghe Institute of Higher Education Global Consortium of Public Health and Research Wardha India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaidhane</LastName><ForeName>Shilpa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Datta Meghe Institute of Higher Education and Research Jawaharlal Nehru Medical College Wardha India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahiruddin</LastName><ForeName>Quazi S</ForeName><Initials>QS</Initials><AffiliationInfo><Affiliation>Division of Evidence Synthesis, Datta Meghe Institute of Higher Education South Asia Infant Feeding Research Network (SAIFRN), Global Consortium of Public Health and Research Wardha India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kukreti</LastName><ForeName>Neelima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Pharmacy Graphic Era Hill University Dehradun India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rustagi</LastName><ForeName>Sarvesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Applied and Life Sciences Uttaranchal University Dehradun India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surana</LastName><ForeName>Arihant</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine St. Vincent Hospital Worcester Massachusetts USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Xacduro</Keyword><Keyword MajorTopicYN="N">acinetobacter</Keyword><Keyword MajorTopicYN="N">durlobactam</Keyword><Keyword MajorTopicYN="N">hospital acquired pneumonia</Keyword><Keyword MajorTopicYN="N">sulbactam</Keyword><Keyword MajorTopicYN="N">ventilator associated pneumonia</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>11</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39257909</ArticleId><ArticleId IdType="pmc">PMC11386240</ArticleId><ArticleId IdType="doi">10.1002/hsr2.70066</ArticleId><ArticleId IdType="pii">HSR270066</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al‐Tawfiq JA, Momattin H, Al‐Ali AY, et al. Antibiotics in the pipeline: a literature review (2017–2020). Infection. 2022;50:553‐564. 10.1007/s15010-021-01709-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01709-3</ArticleId><ArticleId IdType="pmc">PMC8488069</ArticleId><ArticleId IdType="pubmed">34606056</ArticleId></ArticleIdList></Reference><Reference><Citation>Al‐Tawfiq JA, Momattin H, Al‐Ali AY, et al. Correction to: antibiotics in the pipeline: a literature review (2017‐2020). Infection. 2022;50:565‐567. 10.1007/s15010-022-01776-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-022-01776-0</ArticleId><ArticleId IdType="pubmed">35274282</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399:629‐655. 10.1016/S0140-6736(21)02724-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue JM, Zhou Y, Kanakamedala H, Cai B. Burden of illness in carbapenem‐resistant acinetobacter baumannii infections in US hospitals between 2014 and 2019. BMC Infect Dis. 2022;22:36. 10.1186/s12879-021-07024-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-07024-4</ArticleId><ArticleId IdType="pmc">PMC8740340</ArticleId><ArticleId IdType="pubmed">34991499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with acinetobacter baumannii infection: systematic review and meta‐analysis. Clin Microbiol Infect. 2014;20:416‐423. 10.1111/1469-0691.12363</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12363</ArticleId><ArticleId IdType="pubmed">24131374</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem‐resistant acinetobacter baumannii: a systematic review and meta‐analysis. Am J Infect Control. 2019;47:1140‐1145. 10.1016/j.ajic.2019.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2019.03.003</ArticleId><ArticleId IdType="pubmed">31003750</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabour S, Bantle K, Bhatnagar A, et al. Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem‐resistant acinetobacter baumannii tested in the antimicrobial resistance laboratory network‐United States, 2017–2020. Microbiol Spectr. 2024;12:e0282823. 10.1128/spectrum.02828-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02828-23</ArticleId><ArticleId IdType="pmc">PMC10845962</ArticleId><ArticleId IdType="pubmed">38174931</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukovic B, Gajic I, Dimkic I, et al. The first nationwide multicenter study of acinetobacter baumannii recovered in Serbia: emergence of OXA‐72, OXA‐23 and NDM‐1‐producing isolates. Antimicrob Resist Infect Control. 2020;9:101. 10.1186/s13756-020-00769-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-020-00769-8</ArticleId><ArticleId IdType="pmc">PMC7338125</ArticleId><ArticleId IdType="pubmed">32631451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimzadeh G, Rezai MS, Farshidi F. Genotypic patterns of multidrug‐resistant acinetobacter baumannii: a systematic review. Adv Biomed Res. 2023;12:56. 10.4103/abr.abr_434_22</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/abr.abr_434_22</ArticleId><ArticleId IdType="pmc">PMC10186031</ArticleId><ArticleId IdType="pubmed">37200758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta N, Angadi K, Jadhav S. Molecular characterization of carbapenem‐resistant acinetobacter baumannii with special reference to carbapenemases: a systematic review. Infect Drug Resist. 2022;15:7631‐7650. 10.2147/idr.S386641</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/idr.S386641</ArticleId><ArticleId IdType="pmc">PMC9791997</ArticleId><ArticleId IdType="pubmed">36579124</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshwal PR, Fathima R, Aggarwal M, Reddy NS, Tiwari P. A systematic review and meta‐analysis for risk factor profiles in patients with resistant acinetobacter baumannii infection relative to control patients. Int J Risk Saf Med. 2023;34:337‐355. 10.3233/JRS-220037</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JRS-220037</ArticleId><ArticleId IdType="pubmed">37154184</ArticleId></ArticleIdList></Reference><Reference><Citation>De Blasiis MR, Sciurti A, Baccolini V, et al. Impact of antibiotic exposure on antibiotic‐resistant acinetobacter baumannii isolation in intensive care unit patients: a systematic review and meta‐analysis. J Hosp Infect. 2024;143:123‐139. 10.1016/j.jhin.2023.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2023.11.002</ArticleId><ArticleId IdType="pubmed">37972711</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyawasam RM, Julien DA, Jelinski DC, et al. Antimicrobial resistance (AMR) in COVID‐19 patients: a systematic review and meta‐analysis (November 2019–June 2021). Antimicrob Resist Infect Control. 2022;11:45. 10.1186/s13756-022-01085-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-022-01085-z</ArticleId><ArticleId IdType="pmc">PMC8899460</ArticleId><ArticleId IdType="pubmed">35255988</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford BJ, Soucy JPR, Leung V, et al. Antibiotic resistance associated with the COVID‐19 pandemic: a systematic review and meta‐analysis. Clin Microbiol Infect. 2023;29:302‐309. 10.1016/j.cmi.2022.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.12.006</ArticleId><ArticleId IdType="pmc">PMC9733301</ArticleId><ArticleId IdType="pubmed">36509377</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
</Citation></Reference><Reference><Citation>
Carbapenem‐resistant Acinetobacter baumannii (CRAB): An urgent public health threat in United States healthcare facilities. Centers for Disease Control and Prevention; 2021. Accessed January 5, 2024. https://arpsp.cdc.gov/story/cra-urgent-public-health-threat
</Citation></Reference><Reference><Citation>
WHO publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization; 2017. Accessed January 5, 2024. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
</Citation></Reference><Reference><Citation>Kilbas EPK, Kilbas I, Ciftci IH. Molecular epidemiology of carbapenem‐resistant acinetobacter baumannii isolates in Turkiye: systematic review. North Clin Istanb. 2023;10:531‐539. 10.14744/nci.2022.17003</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/nci.2022.17003</ArticleId><ArticleId IdType="pmc">PMC10500232</ArticleId><ArticleId IdType="pubmed">37719251</ArticleId></ArticleIdList></Reference><Reference><Citation>Boral J, Pınarlık F, Ekinci G, Can F, Ergönül Ö. Does emerging carbapenem resistance in acinetobacter baumannii increase the case fatality rate? Systematic review and meta‐analysis. Infect Dis Rep. 2023;15:564‐575. 10.3390/idr15050055</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/idr15050055</ArticleId><ArticleId IdType="pmc">PMC10606343</ArticleId><ArticleId IdType="pubmed">37888136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassoun‐Kheir N, Guedes M, Ngo Nsoga MT, et al. A systematic review on the excess health risk of antibiotic‐resistant bloodstream infections for six key pathogens in Europe. Clin Microbiol Infect. 2023; 30 (Supplement 1):S14‐S25. 10.1016/j.cmi.2023.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.09.001</ArticleId><ArticleId IdType="pubmed">37802750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingston R, Vella V, Pouwels KB, et al. Excess resource use and cost of drug‐resistant infections for six key pathogens in Europe: a systematic review and Bayesian meta‐analysis. Clin Microbiol Infect. 2024;30(suppl 1):26. 10.1016/j.cmi.2023.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.12.013</ArticleId><ArticleId IdType="pubmed">38128781</ArticleId></ArticleIdList></Reference><Reference><Citation>Teerawattanapong N, Panich P, Kulpokin D, et al. A systematic review of the burden of multidrug‐resistant healthcare‐associated infections among intensive care unit patients in Southeast Asia: the rise of multidrug‐resistant acinetobacter baumannii. Infect Control Hosp Epidemiol. 2018;39:525‐533. 10.1017/ice.2018.58</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2018.58</ArticleId><ArticleId IdType="pubmed">29580299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of america 2023 guidance on the treatment of antimicrobial resistant gram‐negative infections. Clin Infect Dis. 2023:ciad428. 10.1093/cid/ciad428</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad428</ArticleId><ArticleId IdType="pubmed">37463564</ArticleId></ArticleIdList></Reference><Reference><Citation>Seok H, Choi WS, Lee S, et al. What is the optimal antibiotic treatment strategy for carbapenem‐resistant acinetobacter baumannii (CRAB)? A multicentre study in Korea. J Glob Antimicrob Resist. 2021;24:429‐439. 10.1016/j.jgar.2021.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgar.2021.01.018</ArticleId><ArticleId IdType="pubmed">33571708</ArticleId></ArticleIdList></Reference><Reference><Citation>Eljaaly K, Bidell MR, Gandhi RG, et al. Colistin nephrotoxicity: meta‐analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8:ofab026. 10.1093/ofid/ofab026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab026</ArticleId><ArticleId IdType="pmc">PMC7888569</ArticleId><ArticleId IdType="pubmed">33623807</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Zhao Y, Jin J, Zhu J, Yu L, Han G. Prevalence and risk factors of tigecycline‐induced liver injury: a multicenter retrospective study. Int J Infect Dis. 2022;120:59‐64. 10.1016/j.ijid.2022.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.04.024</ArticleId><ArticleId IdType="pubmed">35429639</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Zuo C, Yu L, et al. Real‐World data of tigecycline‐associated drug‐induced liver injury among patients in China: a 3‐year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021;12:761167. 10.3389/fphar.2021.761167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.761167</ArticleId><ArticleId IdType="pmc">PMC8594628</ArticleId><ArticleId IdType="pubmed">34795591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei C, Liu Y, Jiang A, Wu B. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on food and drug administration adverse event reporting system data. Int J Clin Pharm. 2022;44:709‐716. 10.1007/s11096-022-01397-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-022-01397-5</ArticleId><ArticleId IdType="pubmed">35364753</ArticleId></ArticleIdList></Reference><Reference><Citation>Rychlíčková J, Kubíčková V, Suk P, Urbánek K. Challenges of colistin use in ICU and therapeutic drug monitoring: a literature review. Antibiotics. 2023;12:437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10044180</ArticleId><ArticleId IdType="pubmed">36978303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital‐acquired and ventilator‐associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of america and the American thoracic society. Clin Infect Dis. 2016;63:e61‐e111. 10.1093/cid/ciw353</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw353</ArticleId><ArticleId IdType="pmc">PMC4981759</ArticleId><ArticleId IdType="pubmed">27418577</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed B, Ishaque S, Imran A, Muslim O, Khalid S, Siddiqui AB. Emergence of colistin‐resistant gram‐negative rods in intensive care units: a cross‐sectional study from a developing country. SAGE Open Med. 2022;10:20503121221132358. 10.1177/20503121221132358</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20503121221132358</ArticleId><ArticleId IdType="pmc">PMC9583228</ArticleId><ArticleId IdType="pubmed">36277441</ArticleId></ArticleIdList></Reference><Reference><Citation>Souli M, Galani I, Giamarellou H. Emergence of extensively drug‐resistant and pandrug‐resistant gram‐negative bacilli in Europe. Euro Surveill. 2008;13:19045.</Citation><ArticleIdList><ArticleId IdType="pubmed">19021957</ArticleId></ArticleIdList></Reference><Reference><Citation>Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem‐resistant acinetobacter baumannii infections. Antimicrob Agents Chemother. 2019;63:e01110‐18. 10.1128/aac.01110-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01110-18</ArticleId><ArticleId IdType="pmc">PMC6325237</ArticleId><ArticleId IdType="pubmed">30323035</ArticleId></ArticleIdList></Reference><Reference><Citation>Al‐Tawfiq JA, Momattin H, Al‐Ali AY, et al. Antibiotics in the pipeline: a literature review (2017–2020). Infection. 2022;50:553‐564. 10.1007/s15010-021-01709-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01709-3</ArticleId><ArticleId IdType="pmc">PMC8488069</ArticleId><ArticleId IdType="pubmed">34606056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasarte‐Monterrubio C, Vazquez‐Ucha JC, Maneiro M, et al. Activity of imipenem, meropenem, cefepime, and sulbactam in combination with the beta‐lactamase inhibitor LN‐1‐255 against acinetobacter spp. Antibiotics (Basel). 2021;10:1‐15. 10.3390/antibiotics10020210</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10020210</ArticleId><ArticleId IdType="pmc">PMC7924334</ArticleId><ArticleId IdType="pubmed">33672671</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA Approves New Treatment for Pneumonia Caused by Certain Difficult‐to‐Treat Bacteria. The United States Food and Drug Administration; 2023. Accessed January 5, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria
</Citation></Reference><Reference><Citation>Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In vitro activity of sulbactam‐durlobactam against global isolates of acinetobacter baumannii‐calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother. 2022;66:e0078122. 10.1128/aac.00781-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00781-22</ArticleId><ArticleId IdType="pmc">PMC9487466</ArticleId><ArticleId IdType="pubmed">36005804</ArticleId></ArticleIdList></Reference><Reference><Citation>Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:1680‐1689. 10.1128/aac.04808-14</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.04808-14</ArticleId><ArticleId IdType="pmc">PMC4325763</ArticleId><ArticleId IdType="pubmed">25561334</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp‐Wallace KM, Senkfor B, Gatta J, et al. Early insights into the interactions of different β‐Lactam antibiotics and β‐Lactamase inhibitors against soluble forms of acinetobacter baumannii PBP1a and acinetobacter sp. PBP3. Antimicrob Agents Chemother. 2012;56:5687‐5692. 10.1128/AAC.01027-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01027-12</ArticleId><ArticleId IdType="pmc">PMC3486531</ArticleId><ArticleId IdType="pubmed">22908165</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyachiro MM, Contreras‐Martel C, Dessen A. Penicillin‐Binding Proteins (PBPs) and Bacterial Cell Wall Elongation ComplexesIn: Harris JR, Marles‐Wright J, eds. Macromolecular protein complexes II: Structure and function. Springer International Publishing; 2019:273‐289.</Citation></Reference><Reference><Citation>Macheboeuf P, Contreras‐Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev. 2006;30:673‐691. 10.1111/j.1574-6976.2006.00024.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2006.00024.x</ArticleId><ArticleId IdType="pubmed">16911039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin‐binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32:234‐258. 10.1111/j.1574-6976.2008.00105.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2008.00105.x</ArticleId><ArticleId IdType="pubmed">18266856</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro AB. Kinetics of sulbactam hydrolysis by β‐Lactamases, and kinetics of β‐Lactamase inhibition by sulbactam. Antimicrob Agents Chemother. 2017;61:e01612‐17. 10.1128/AAC.01612-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01612-17</ArticleId><ArticleId IdType="pmc">PMC5700308</ArticleId><ArticleId IdType="pubmed">28971872</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert H, Müller C, Stefanik D, Higgins PG, Miller A, Kresken M. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem‐resistant acinetobacter baumannii. J Antimicrob Chemother. 2020;75:2616‐2621. 10.1093/jac/dkaa208</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa208</ArticleId><ArticleId IdType="pubmed">32516359</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro AB, Moussa SH, McLeod SM, Durand‐Réville T, Miller AA. Durlobactam, a new diazabicyclooctane β‐Lactamase inhibitor for the treatment of acinetobacter infections in combination with sulbactam. Front Microbiol. 2021;12:709974. 10.3389/fmicb.2021.709974</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.709974</ArticleId><ArticleId IdType="pmc">PMC8328114</ArticleId><ArticleId IdType="pubmed">34349751</ArticleId></ArticleIdList></Reference><Reference><Citation>Jean SS, Chang YC, Lin WC, Lee WS, Hsueh PR, Hsu CW. Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. J Clin Med. 2020;9:275. 10.3390/jcm9010275</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9010275</ArticleId><ArticleId IdType="pmc">PMC7019939</ArticleId><ArticleId IdType="pubmed">31963877</ArticleId></ArticleIdList></Reference><Reference><Citation>Principe L, Di Bella S, Conti J, et al. Acinetobacter baumannii resistance to sulbactam/durlobactam: a systematic review. Antibiotics (Basel). 2022;11:1793. 10.3390/antibiotics11121793</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11121793</ArticleId><ArticleId IdType="pmc">PMC9774100</ArticleId><ArticleId IdType="pubmed">36551450</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Chen L, Yue M, Huang X, Yang Y, Yu H. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug‐resistant acinetobacter baumannii pneumonia. BMC Infect Dis. 2022;22:795. 10.1186/s12879-022-07778-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07778-5</ArticleId><ArticleId IdType="pmc">PMC9585752</ArticleId><ArticleId IdType="pubmed">36271362</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R. Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects. Antimicrob Agents Chemother. 2019;63:e00794‐19. 10.1128/AAC.00794-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00794-19</ArticleId><ArticleId IdType="pmc">PMC6709459</ArticleId><ArticleId IdType="pubmed">31307978</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagan O, Yakubsevitch R, Yanev K, et al. Pharmacokinetics and tolerability of intravenous sulbactam‐durlobactam with imipenem‐cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. Antimicrob Agents Chemother. 2020;64:e01506‐19. 10.1128/AAC.01506-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01506-19</ArticleId><ArticleId IdType="pmc">PMC7038258</ArticleId><ArticleId IdType="pubmed">31843995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam‐durlobactam versus colistin for the treatment of patients with serious infections caused by acinetobacter baumannii‐calcoaceticus complex: a multicentre, randomised, active‐controlled, phase 3, non‐inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23:1072‐1084. 10.1016/s1473-3099(23)00184-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(23)00184-6</ArticleId><ArticleId IdType="pubmed">37182534</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care. 2004;8:R204‐R212. 10.1186/cc2872</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc2872</ArticleId><ArticleId IdType="pmc">PMC522841</ArticleId><ArticleId IdType="pubmed">15312219</ArticleId></ArticleIdList></Reference><Reference><Citation>
Drug Approval Package: XACDURO. The United States Food and Drug Administration; 2023. Accessed January 5, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216974Orig1s000TOC.cfm
</Citation></Reference><Reference><Citation>Anand A, Parveen Shaikh N, Aggarwal Y, et al. Vowst's FDA approval is a boon for the prevention of recurrent clostridioides difficile infection. Ann Med Surg (Lond). 2023;85:5852‐5854. 10.1097/ms9.0000000000001410</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ms9.0000000000001410</ArticleId><ArticleId IdType="pmc">PMC10718391</ArticleId><ArticleId IdType="pubmed">38098563</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilnessa T, Getaneh A, Hailu W, Moges F, Gelaw B. Prevalence and antimicrobial resistance pattern of clostridium difficile among hospitalized diarrheal patients: a systematic review and meta‐analysis. PLoS One. 2022;17:e0262597. 10.1371/journal.pone.0262597</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262597</ArticleId><ArticleId IdType="pmc">PMC8758073</ArticleId><ArticleId IdType="pubmed">35025959</ArticleId></ArticleIdList></Reference><Reference><Citation>Motamedi H, Fathollahi M, Abiri R, Kadivarian S, Rostamian M, Alvandi A. A worldwide systematic review and meta‐analysis of bacteria related to antibiotic‐associated diarrhea in hospitalized patients. PLoS One. 2021;16:e0260667. 10.1371/journal.pone.0260667</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260667</ArticleId><ArticleId IdType="pmc">PMC8654158</ArticleId><ArticleId IdType="pubmed">34879104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen S, Wang C, Duan Y, et al. OAT1 and OAT3 also mediate the drug‐drug interaction between piperacillin and tazobactam. Int J Pharm. 2018;537:172‐182. 10.1016/j.ijpharm.2017.12.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2017.12.037</ArticleId><ArticleId IdType="pubmed">29277663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartal C, Rolston KVI, Nesher L. Carbapenem‐resistant acinetobacter baumannii: colonization, infection and current treatment options. Infect Dis Ther. 2022;11:683‐694. 10.1007/s40121-022-00597-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00597-w</ArticleId><ArticleId IdType="pmc">PMC8960525</ArticleId><ArticleId IdType="pubmed">35175509</ArticleId></ArticleIdList></Reference><Reference><Citation>Beninger P. Sulbactam/durlobactam. Clin Ther. 2024;46:82‐83. 10.1016/j.clinthera.2023.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2023.11.009</ArticleId><ArticleId IdType="pubmed">38065814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>